- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,240 | 03.07.24 17:35:33 | -0,180 | -0,20% | 0,000 | 0,000 | 90,890 | 90,420 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.024,090 | 03.07.24 19:00:03 | -20,570 | -1,97% | 1.010,000 | 1.034,190 | 1.042,280 | 1.044,660 |
